In the current trading session, at the last check, the CUE stock had surged by 29.88% to $14.62. CUE’s stock previously closed at $11.26. The CUE stock volume traded 7.72 million shares. The average trade volume for 3 months was 281.11K. The company is valued at $332.51 million and has 30.30 million outstanding shares.
Cue announces positive report for PR in ongoing Phase 1 Monotherapy Study of CUE-101
Today on 10th May 2021, the company reported interim clinical data, including an affirmed halfway reaction (PR), from its continuous Phase 1a/1b monotherapy investigation of CUE-101 as second-line treatment for patients with HPV+ R/M HNSCC. Until this point, CUE-101 has shown a great bearableness profile in a monotherapy portion heightening preliminary and keenly encourages new datasets to its pharmacokinetic (PK) and pharmacodynamic (PD) profiles, just as clinical anti-tumor action.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Key interval investigation of patient information from the ongoing open-label Phase 1a/1b examination includes; Affirmed PR in one patient and SD in five patients, all affirmed by RECIST measures, in the portion heightening period of the investigation to date, giving early indications of potential single-specialist movement of CUE-101. The investigations demonstrated proof of both tumor-explicit CD8+ T cell extensions just as portion subordinate expansions in NK cells in patients.
The study detected safe cell penetration and tumor cell necrosis in patient tumor biopsies after CUE-101 treatment, supporting CUE-101’s system of activity at drawing in and balancing focused on T cells inside the patient’s body. Furthermore, dose-proportional PK profile and similar medication exposure levels in patients getting continued dosing cycles, steady with an absence of medication clearing against drug antibodies. The experiments resulted in no most extreme endured portion (MTD) saw in patients dosed with up to 8 mg/kg of CUE-101.
The road ahead for the clinical action of CUE-101
Accepting early affirmation of clinical action of CUE-101 as a monotherapy in this difficult patient populace is a significant approval of the capability of the CUE-101 program for oncology. CUE stock expects various significant achievements over time with the capability of additional information to illuminate CUE-101’s clinical application.
These achievements incorporate, the likely choice of a suggested Phase 2 portion of CUE-101 by mid-2021 as stated by the company, for additional improvement as a solitary specialist treatment for HPV+ 2L+ head and neck squamous cell carcinoma. The company plans to report introductory Phase 1 outcome from the mix investigation of CUE-101 with pembrolizumab in the second 50% of 2021 and furthermore plans to start a Phase 2 neoadjuvant study to assess the impacts of CUE-101 on the tumor microenvironment, which is likewise expected to begin in the second 50% of 2021.
About Prompt Bipharma Inc.
Prompt Biopharma, Inc., is a biopharmaceutical organization that specifically focuses on creating biological medications for the particular adjustment of the human immune system framework to treat a scope of tumors, persistent irresistible sicknesses, and immune system issues. The organization was once in the past known as Imagen Biopharma, Inc. what’s more, changed its name to Cue Biopharma, Inc. in October 2016. Sign Biopharma, Inc. was established in 2014 and is settled in Cambridge, Massachusetts.
The organization offers CUE-102, an oncofetal viral antigen for tumors, including strong tumors and hematologic malignancies; CUE-103, an antigen; CUE-200 system that incorporates CD80 or potentially 4-1BBL to reactivate depleted T cells and configuration to improve antigen-explicit T cell for the therapy of constant irresistible illnesses; and CUE-300 structure to target different immune system infections.
